Acadia Pharma Q3 2024 Earnings Preview
by
Contributor since / Followers
Contributor since / Followers
5 months ago
Acadia Pharma (NASDAQ:ACAD) is scheduled to announce Q3 earnings results on Wednesday, November 6th, after
ACAD
Acadia sells Rare Pediatric Disease Priority Review Voucher for $150M
by
Contributor since / Followers
Contributor since / Followers
5 months ago
hapabapa Acadia Pharmaceuticals (NASDAQ:ACAD) has sold a Rare Pediatric Disease Priority Review Voucher for $150M.
Catherine Owen appointed as CEO of Acadia Pharmaceuticals
by
Contributor since / Followers
Contributor since / Followers
7 months ago
Acadia Pharmaceuticals (NASDAQ:ACAD) announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
by ONeil Trader
Contributor since 2012 / 8517 Followers
Contributor since 2012 / 8517 Followers
8 months ago
Summary: Shares of Acadia trended lower this year due to Daybue’s poor quarterly sales performance,
ACADIA Pharma cut at Morgan Stanley on Daybue miss
by
Contributor since / Followers
Contributor since / Followers
8 months ago
LeoPatrizi Despite ACADIA Pharmaceuticals’ (NASDAQ:ACAD) Q2 beat yesterday, Morgan Stanley downgraded the stock on Wednesday,
Acadia Pharma GAAP EPS of $0.20 beats by $0.03, revenue of $241.96M beats by $6.3M
by
Contributor since / Followers
Contributor since / Followers
8 months ago
Acadia Pharma press release (NASDAQ:ACAD): Q2 GAAP EPS of $0.20 beats by $0.03. Revenue of
Acadia Pharma Q2 2024 Earnings Preview
by
Contributor since / Followers
Contributor since / Followers
8 months ago
Acadia Pharma (NASDAQ:ACAD) is scheduled to announce Q2 earnings results on Tuesday, August 6th, after
Acadia Pharmaceuticals: Back In The Buy Zone
by Bret Jensen
Contributor since 2010 / 49448 Followers
Contributor since 2010 / 49448 Followers
10 months ago
Summary: Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to
Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments
by Myriam Alvarez
Contributor since 2023 / 1145 Followers
Contributor since 2023 / 1145 Followers
10 months ago
Summary: ACADIA Pharmaceuticals is a biopharmaceutical company specializing in CNS disorder treatments, with two successful
Cantor picks 14 undervalued biotech stocks worth a second look
by
Contributor since / Followers
Contributor since / Followers
11 months ago
jittawit.21 Cantor Fitzgerald has selected its 14 top picks for biotech stocks that it regards